Advancing Novel T Cell Engaging Immunotherapies
Harpoon is a clinical-stage immuno-oncology company building a pipeline of wholly-owned immunotherapies harnessing the tumor-killing power of T cells for patients with difficult-to-treat tumors.
1. Roche supply agreement established for the use of atezolizumab in combination with HPN328
2. Research collaboration with AbbVie to select a fixed number of targets from these platforms
For a description of our ongoing clinical studies, please visit clinicaltrials.gov.
For expanded access visit Expanded Access Policy.